July 2025 Vol 18, No 3
HemOnc.org aims to provide consistently structured, evidence-based, and up-to-date information that is not only clinically relevant but also immediately usable to everyone, including pharmacists, other healthcare providers, and patients. Read More ›
The use of circulating tumor DNA is emerging as a powerful tool in colorectal cancer management, but its potential to address disparities in care remains an ongoing challenge. Read More ›
The phase 3 S2302 Pragmatica-Lung study offers a new blueprint for cancer clinical trials, one that emphasizes simplification, inclusivity, and real-world applicability, according to Konstantin Dragnev, MD, of Dartmouth Cancer Center. Read More ›
Nurses and navigators, especially those embedded in community programs, can help bridge the access gap by promoting education, building trust, and facilitating access early in the patient journey. Read More ›
Advances in technology, including artificial intelligence and telemedicine platforms, offer promising avenues to support precision oncology efforts remotely. Read More ›
Despite their therapeutic potential, the adoption and utilization of bispecific antibodies exhibit significant disparities, particularly between urban and rural healthcare settings. Read More ›